Writing Group Disclosures
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/ honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Elizabeth M. McNally | Northwestern University | None | None | None | None | Ikaika Therapeutics* | None | None |
| Mitchell S.V. Elkind | Columbia University | None | None | None | None | None | None | None |
| Ivor J. Benjamin | Medical College of Wisconsin | None | None | None | None | None | None | None |
| Mina K. Chung | Cleveland Clinic | NIH†; AHA† | None | None | None | None | None | None |
| Glenn H. Dillon | American Heart Association | None | None | None | None | None | None | None |
| Adrian F. Hernandez | Duke University | AstraZeneca*; Boehringer Ingelheim*; Merck*; Novartis*; Verily* | None | None | None | None | AstraZeneca*; Bayer*; Boston Scientific*; Merck*; Myokardia* | None |
| Chinwe Ibeh | Columbia University Irving Medical Center and New York–Presbyterian Hospital | None | None | None | None | None | None | None |
| Donald M. Lloyd-Jones | Northwestern University | None | None | None | None | None | None | None |
| Louise D. McCullough | The University of Texas Health Science Center at Houston | None | None | None | None | None | None | None |
| Loren E. Wold | The Ohio State University | NIH (R01 and U01)†; AHA† | None | None | None | None | None | None |
| Davene R. Wright | HMS and Harvard Pilgrim Health Care Institute | None | None | None | None | None | None | None |
| Joseph C. Wu | Stanford University | NIH† | None | None | None | Khloris Bio-sciences† | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.